Newsfiscal.ai
Needham Maintains Buy Rating on CorMedix, Lowers Price Target
· Published
Article summary
Needham analyst Serge Belanger reiterated a Buy rating on CorMedix while adjusting the price target to $12 from $15.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…


Comments —
Loading comments…